Skip to Content
Merck
All Photos(1)

Documents

C-053

Supelco

Carbamazepine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H12N2O
CAS Number:
Molecular Weight:
236.27
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O=C(N)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

General description

Carbamazepine is an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and neuropathic pain. Marketed under trade names including Carbatrol®, Tegretol®, Carbamaze, and Biston, carbamazepine is also used as a second line treatment for bipolar disorder and in conjunction with antipsychotic drugs for schizophrenia. Suitable uses of this Certified Spiking Solution® include as starting material for preparation of calibrators and controls in carbamazepine testing methods by GC/MS or LC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or therapeutic drug monitoring applications.

Application


  • Carbamazepine research solution: A study focuses on the development of cobalt-nitrogen co-doped carbon nanotubes for the activated peroxymonosulfate degradation of Carbamazepine, highlighting its applications in environmental cleanup and pollution control (Molecules, 2024; doi: 10.3390/molecules29071525).

  • Anticonvulsant biochemical reagent: Carbamazepine is utilized in research involving the production and characterization of activated carbon for removing pharmaceutical pollutants from various water sources, demonstrating its relevance in sustainable water treatment technologies. (Materials, Basel).

  • Neuroscience research chemicals: Investigations into novel composite materials for the removal of pharmaceuticals from water matrices include Carbamazepine as a target contaminant, emphasizing its importance in studies related to environmental health and safety (Environ Res, et.al).

  • Ion channel inhibitor: Research into new materials for drug residue removal includes Carbamazepine, showcasing its utility in evaluating the performance of innovative water treatment solutions (Carbohydr Polym, 2024).

  • Epilepsy pharmacological studies: A study involving the LED-driven photo-Fenton process for micropollutant removal highlights the application of Carbamazepine in assessing the efficacy of advanced oxidative processes for environmental decontamination (J Environ Manage, 2024).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Carbatrol is a registered trademark of Pharmavene, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tegretol is a registered trademark of Novartis Corporation

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Skin Sens. 1 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Emilie Caietta et al.
Pediatrics, 132(3), e784-e787 (2013-08-21)
Mutations of SCN4A encoding the skeletal muscle sodium channel Nav 1.4 cause several types of disease, including sodium channel myotonias. The latter may be responsible for neonatal symptoms, including severe neonatal episodic laryngospasm (SNEL). Establishing the diagnosis of SCN4A-related SNEL
U Amstutz et al.
Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)
The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers
Inge Anita Meijer et al.
Muscle & nerve, 49(1), 134-138 (2013-07-31)
Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities. We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and

Articles

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service